TrialCancer science2021

Greater extent of blood-tumor TCR repertoire overlap is associated with favorable clinical responses to PD-1 blockade.

Hiroyasu Aoki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.